Real-World Healthcare Intelligence Challenges Solved by MedLii AI

"Compare Merck, Bristol Myers Squibb, AstraZeneca, Roche, and Gilead's global CAR-T and TCR-T oncology pipelines. Identify assets in Phase II and above, compare mechanisms of action, estimate launch timing, evaluate competitive threats to Miltenyi's Zamtocel program, and provide a SWOT analysis with supporting references."

"Identify the top 20 oncology clinical trial sites in India with experience in CAR-T therapies. Evaluate historical enrollment performance, investigator experience, competing studies, and recommend the optimal sites for a Phase II relapsed/refractory lymphoma study."

"Evaluate a Phase II obesity asset targeting GLP-1 and GIP receptors. Compare against Wegovy, Zepbound, and oral GLP-1 competitors. Estimate commercial opportunity, regulatory risk, payer adoption, and licensing attractiveness through 2035."

"Review all major ASCO, ESMO, AACR, and SABCS presentations published during the last 24 months in metastatic breast cancer. Summarize clinically meaningful developments and identify emerging treatment trends likely to impact treatment guidelines."

"Compare FDA, EMA, MHRA, PMDA, and CDSCO regulatory expectations for autologous CAR-T products. Highlight differences in CMC requirements, post-marketing commitments, long-term follow-up obligations, and risk management plans."

"Develop a market access strategy for a first-in-class gene therapy targeting a rare hematological disease in India, Germany, the United Kingdom, and the United States. Evaluate payer barriers, reimbursement pathways, HTA requirements, and pricing risks."

"Prepare a board-level briefing on the global obesity market through 2035. Include epidemiology trends, competitive landscape, pipeline analysis, payer concerns, patent expiries, and expected market disruption scenarios."

"Review all high-impact publications in Nature, Lancet Oncology, New England Journal of Medicine, JAMA Oncology, and Blood relating to CAR-T therapies published within the last 36 months. Summarize evidence, identify consensus themes, and highlight unresolved scientific questions."

"Develop a global launch strategy for an oncology therapy expected to receive FDA approval in Q2 2027. Include medical affairs planning, KOL engagement, market access preparation, competitive defense strategies, and launch readiness milestones."

"Conduct a comprehensive assessment of all approved and investigational CAR-T therapies worldwide. Compare efficacy, safety, manufacturing complexity, reimbursement status, market share, pipeline expansion opportunities, and future technology trends."